MRS can detect brain tumor biomarker

Many patients with a form of brain cancer called glioma have mutations in two genes that code for enzymes, IDH1 and IDH2. These changes result in increased levels of a compound called 2-hydroxyglutarate (2HG), seen in 80% of low- and intermediate-grade gliomas, and this biomarker can be detected using magnetic resonance spectroscopy (MRS). In a technical report published in Nature Medicine, researchers from University of Texas Southwestern Medical Center confirmed the technique's efficacy by analyzing tumors from 30 patients. They suggested that 2HG could be a valuable diagnostic and prognostic biomarker, as patients with this mutation tend to have better outcomes. Article | Abstract

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.